

Minutes

IBC Meeting

Date: June 4, 2025

Time: 3PM

Location: Zoom Meeting – Meeting ID 988 0180 6074

Call-in number: 301-715-8592

Attendees: Jermaine Lawson, Kenta Umetsu, James Novak, Stephanie Gomez, Beata Jablonska, Lumen Chao, Sydney Villanueva, Kenneth Dolan, Marissa Horrigan, Daniel Bobb

Members Absent: Cristano Escano, Michael Keller, Kerry Belton

Guests: None

Agenda Topic	Discussion Lead	Notes	Time
Call to Order	Jermaine Lawson	The meeting was called to order when quorum was fulfilled. Attendance was documented by the administrator.	3:17PM
Meeting Minutes	Jermaine Lawson	The minutes for the 04/08/2025 were approved before the meeting via Teams. <u>Vote</u>	3:18PM



Children's National®

Minutes

		<p>Approve = 8</p> <p>Oppose = 0</p> <p>Abstain = 1</p> <p>Defer = 0</p> <p>A discussion was also had regarding the new NIH requirement to make IBC minutes publicly available.</p>	
Announcements	Jermaine Lawson	<ul style="list-style-type: none">• Jermaine Lawson provided an update on protocol 10032-IBC-Hsieh that project PI withdrew protocol submission and terminated project.• Jermaine Lawson informed the committee of the executive order on Improving the Safety and Security of Biological Research.	3:18PM
Protocol Review	Jermaine Lawson	<p>New Protocol Submission: 25-10070-IBC-Fonseca</p> <p>Principal Investigator – Adriana Fonseca Sheridan</p>	3:23PM

Minutes



		<p>Protocol Title – Developing preclinical models for rare brain tumors and testing novel therapeutic strategies</p> <p><u>Committee Action</u></p> <p>Full committee review of protocol 25-10070, which was a new submission for the use of lentiviral vectors, non-viral vectors and human source materials.</p> <p><u>Project Summary</u></p> <p>The lab studies pediatric rare brain tumors (RBTs) with the objective to deepen our understanding of the biological mechanisms of the RBTs and to generate needed data that can lead to new treatment strategies for children with rare entities.</p> <p>The project summary was presented by Jermaine Lawson followed by discussion of project by the committee.</p> <p><u>Remarks</u></p> <p>The committee identified the following minor issues to be addressed by project PI after review and discussion of the submitted project.</p>	
--	--	---	--

Minutes



		<ul style="list-style-type: none">• There are typographical errors in the project that summary that needs to be addressed by project PI.• Project PI needs to answer section 3D on proprietary information.• Project PI needs to indicate in the risk assessment section that using a double cassette lentiviral vector for CRISPR application increases risk of gene editing.• Project PI needs to add helper plasmids that are used for generation of lentivirus.• The biosafety level for LentiCRISPRv2 construct should be changed to BSL-2+.• Project PI needs to indicate source on non-viral vector.• PI needs to state that human iPSCs will be administered to mice, then indicate animal biosafety level 2, the associated IACUC information, and work location.	
--	--	--	--

Minutes



		<p><u>Vote</u></p> <p>The committee voted to approve the protocol.</p> <p>Approve = 9 Oppose = 0 Abstain = 0 Defer = 0</p>	
Protocol Review	Jermaine Lawson	<p>New Protocol Submission: 25-10069-IBC-Hogarth Project PI – Marshall Hogarth Protocol Title – Modulating the fate of muscle-resident mesenchymal progenitors</p> <p><u>Committee Action</u></p> <p>Full committee review of protocol 25-10069, which was a new submission for the use of human derived material.</p> <p><u>Project Summary</u></p> <p>The Hogarth lab focuses on developing therapies to slow the progression of muscle weakness in patients with muscular Dystrophies. In these diseases, there is excessive accumulation and differentiation of muscle-resident mesenchymal cells that lead to the replacement of functional muscle fibers</p>	3:37PM

Minutes



		<p>with fibrotic and/or adaptogenic deposits.</p> <p>The project summary was presented by Jermaine Lawson followed by protocol discussion by the committee.</p> <p><u>Remarks</u></p> <p>The committee identified the following minor issues to be addressed by project PI after review and discussion of the submitted project.</p> <ul style="list-style-type: none">• The name of the research center needs to be updated to reflect the recent name change.• There are typographical errors in the project summary that the project PI needs to address.• Project PI needs to answer section 3D on proprietary information.• Project PI needs to change the risk group selection to risk group 2 in the risk assessment section for human derived material.• Transport of biological material using a leak proof secondary container needs to be selected.	
--	--	--	--



Children's National®

Minutes

		<ul style="list-style-type: none">Disposal of sharps in a puncture resistant container with biohazard symbol needs to be selected. <p><u>Vote</u></p> <p>The committee voted to approve the protocol.</p> <p>Approve = 9 Oppose = 0 Abstain = 0 Defer = 0</p>	
Adjournment	Jermaine Lawson	The meeting was adjourned at 3:49PM.	3:49PM